NASDAQ:EUCR

Eucrates Biomedical Acquisition Stock Forecast, Price & News

$10.12

+0.10 (+1.00 %)

(As of 03/8/2021 12:00 AM ET)

Add

Compare

Today's Range

$10.10

Now: $10.12▼

$10.12

50-Day Range

$10.02

MA: $10.39▼

$10.64

52-Week Range

$9.76

Now: $10.12▼

$10.88

Volume1,200 shs

Average Volume29,518 shs

Market Capitalization$136.21 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Eucrates Biomedical Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in New York, New York.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Shell Companies

Sub-IndustryN/A

SectorUnclassified

Current SymbolNASDAQ:EUCR

Previous Symbol

CUSIPN/A

CIKN/A

WebN/A

Phone212-710-5220

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares13,459,000

Market Cap$136.21 million

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

Unclassified Sector

190th out of 246 stocks

Shell Companies Industry

202nd out of 281 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Eucrates Biomedical Acquisition.

0.0 Community Rank

Outperform Votes
Eucrates Biomedical Acquisition has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Eucrates Biomedical Acquisition has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Eucrates Biomedical Acquisition and other stocks. Vote “Outperform” if you believe EUCR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EUCR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Eucrates Biomedical Acquisition does not currently pay a dividend.
Dividend Growth
Eucrates Biomedical Acquisition does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eucrates Biomedical Acquisition insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$10.12

+0.10 (+1.00 %)

(As of 03/8/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive EUCR News and Ratings via Email

Sign-up to receive the latest news and ratings for EUCR and its competitors with MarketBeat's FREE daily newsletter.

Eucrates Biomedical Acquisition (NASDAQ:EUCR) Frequently Asked Questions

What stocks does MarketBeat like better than Eucrates Biomedical Acquisition?

Wall Street analysts have given Eucrates Biomedical Acquisition a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Eucrates Biomedical Acquisition wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Eucrates Biomedical Acquisition's key executives?

Eucrates Biomedical Acquisition's management team includes the following people:

Mr. Parag Phoolchand Saxena MBA, MS, CEO & Director (Age 65)
Dr. Evangelos Vergetis, Pres, COO & Director (Age 42)
Mr. Gonzalo Cordova CFA, Chief Financial Officer (Age 66)
Mr. Shrikant Sathe, Sr. VP (Age 67)

Who are some of Eucrates Biomedical Acquisition's key competitors?

Some companies that are related to Eucrates Biomedical Acquisition include Altimeter Growth Corp. 2 (AGCB), Montes Archimedes Acquisition (MAAC), Senior Connect Acquisition Corp. I (SNRH), Supernova Partners Acquisition (SPNV), Carney Technology Acquisition Corp. II (CTAQ), Investindustrial Acquisition (IIAC), Cerberus Telecom Acquisition (CTAC), NextGen Acquisition (NGAC), H.I.G. Acquisition (HIGA), Lux Health Tech Acquisition (LUXA), RMG Acquisition Co. II (RMGB), Holicity (HOL), FinServ Acquisition (FSRV), Jaws Spitfire Acquisition (SPFR) and Northern Star Investment Corp. II (NSTB).
View all of EUCR's competitors.

What is Eucrates Biomedical Acquisition's stock symbol?

Eucrates Biomedical Acquisition trades on the NASDAQ under the ticker symbol "EUCR."

Who are Eucrates Biomedical Acquisition's major shareholders?

Eucrates Biomedical Acquisition's stock is owned by many different institutional and retail investors. Top institutional shareholders include Hudson Bay Capital Management LP (2.97%), Granite Point Capital Management L.P. (2.84%) and Radcliffe Capital Management L.P. (0.74%).

Which institutional investors are buying Eucrates Biomedical Acquisition stock?

EUCR stock was purchased by a variety of institutional investors in the last quarter, including Hudson Bay Capital Management LP, Granite Point Capital Management L.P., and Radcliffe Capital Management L.P..

How do I buy shares of Eucrates Biomedical Acquisition?

Shares of EUCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eucrates Biomedical Acquisition's stock price today?

One share of EUCR stock can currently be purchased for approximately $10.12.

How much money does Eucrates Biomedical Acquisition make?

Eucrates Biomedical Acquisition has a market capitalization of $136.21 million.

Where are Eucrates Biomedical Acquisition's headquarters?

Eucrates Biomedical Acquisition is headquartered at 250 WEST 55TH STREET SUITE 13D, NEW YORK NY, 10019.

How can I contact Eucrates Biomedical Acquisition?

Eucrates Biomedical Acquisition's mailing address is 250 WEST 55TH STREET SUITE 13D, NEW YORK NY, 10019. The company can be reached via phone at 212-710-5220.

This page was last updated on 3/8/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here